Key Highlights

  • Accuray designs and sells advanced radiotherapy and radiosurgery systems used to treat cancer, anchored by its CyberKnife and TomoTherapy/Radixact platforms and a substantial service business.
  • For fiscal 2026, Accuray reported full-year Revenue of about $402 million, down 12%, with fourth-quarter revenue of $100.9 million, down 21% year over year.
  • The pivotal near-term event is the stockholder meeting scheduled for October 6, 2026, where investors vote on the Recapitalization and the reverse-split authorization, proposed in a range of 1-for-15 to 1-for-40.
  • The recapitalization and reverse split are highly dilutive, potentially adding well over 100 million shares and sharply reducing existing holders' ownership.

Few established med-tech names have had a rougher stretch than Accuray Incorporated (NASDAQ:ARAY). The maker of the CyberKnife and TomoTherapy radiation-oncology systems has watched its stock sink well below $1, and in early September 2026 the shares slipped further.

Behind the decline lies a genuine corporate overhaul: a $55 million recapitalization, a looming reverse stock split, and a fight to keep its Nasdaq listing. For a company with a respected clinical franchise, this financial reset marks a critical juncture.

Company and Latest Development

Accuray designs and sells advanced radiotherapy and radiosurgery systems used to treat cancer, anchored by its CyberKnife and TomoTherapy/Radixact platforms and a substantial service business. The defining recent development is financial rather than clinical. In 2026 Accuray agreed a comprehensive recapitalization with lender TCW, converting $40 million of existing Debt into convertible preferred equity, adding a $15 million cash investment, and securing a covenant holiday through December 2027. The board also proposed a Reverse Stock Split to help restore compliance with Nasdaq's minimum bid-price rule.

What Is Driving Attention Around ARAY?

Attention on ARAY is squarely tied to its balance-sheet crisis and turnaround, not to a discrete one-day catalyst. The stock's collapse below $1 reflects weak product sales, an operating loss, and going-concern pressures disclosed in company filings. Accuray's fiscal fourth-quarter results, reported on August 19, 2026, showed revenue falling and losses widening, reinforcing the case for the recapitalization. The early-September drift lower is consistent with uncertainty ahead of a stockholder vote rather than any fresh, separately confirmed piece of news.

Key Numbers and Company Position

For fiscal 2026, Accuray reported full-year revenue of about $402 million, down 12%, with fourth-quarter revenue of $100.9 million, down 21% year over year. Service revenue rose to roughly $229 million while product revenue fell to about $173 million. The company swung to a full-year operating loss of about $26.4 million and ended the period with total Liquidity near $48.8 million. The recapitalization adds $55 million in combined debt conversion and cash, and management said it exceeded $20 million in cost and Margin improvements against a $12 million goal.

What Could Come Next?

The pivotal near-term event is the stockholder meeting scheduled for October 6, 2026, where investors vote on the recapitalization and the reverse-split authorization, proposed in a range of 1-for-15 to 1-for-40. Accuray faces a Nasdaq milestone requiring a $1.00 closing bid for ten consecutive Business days, with a stated compliance date of February 1, 2027. Investors may also watch fiscal 2027 order trends and whether cost savings translate into improved margins, though management withheld formal guidance.

Risks to Watch

The risks are acute. The recapitalization and reverse split are highly dilutive, potentially adding well over 100 million shares and sharply reducing existing holders' ownership. Failure to regain Nasdaq compliance could threaten the listing. Going-concern language, Tariff and geopolitical pressures, and soft product Demand all weigh on the outlook. Even if the Balance Sheet is repaired, Accuray must still reverse declining sales in a competitive radiation-oncology market dominated by larger rivals.

Accuray's story in September 2026 is one of financial triage. A $55 million TCW recapitalization and a planned reverse split aim to stabilize the balance sheet and preserve its Nasdaq listing, but at a steep cost to current shareholders. The October 6 vote and the February 2027 compliance deadline are the events to monitor, alongside any sign that revenue and margins are turning. Accuray's clinical Franchise is real; whether it can be rebuilt into Shareholder value is the open question.